tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Glen Santangelo, 159 are a BUY (69.13%), 68 are a HOLD (29.57%), 3 are a SELL (1.3%).
Analyst Glen Santangelo, currently employed at BARCLAYS, carries an average stock price target met ratio of 58.18% that have a potential upside of 22.99% achieved within 208 days. Previously, Glen Santangelo worked at JEFFERIES.
Glen Santangelo’s has documented 437 price targets and ratings displayed on 47 stocks. The coverage is on Healthcare, Consumer Defensive, Technology sectors.
Most recent stock forecast was given on PHAT, Phathom Pharmaceuticals at 27-Mar-2026.
Analyst best performing recommendations are on INO (INOVIO PHARMACEUTICALS).
The best stock recommendation documented was for INO (INOVIO PHARMACEUTICALS) at 6/11/2020. The price target of $312 was fulfilled within 14 days with a profit of $165.84 (113.46%) receiving and performance score of 81.05.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 10-Oct-2017
$215
$40.04 (22.89%)
$187
2 years 7 months 27 days ago
(07-Aug-2023)
15/16 (93.75%)
$28.91 (15.54%)
636
Hold Since 27-May-2022
$190
$15.04 (8.60%)
$176
2 years 8 months ago
(03-Aug-2023)
12/12 (100%)
$-0.86 (-0.45%)
392
Buy Since 05-Aug-2021
$220
$45.04 (25.74%)
$213
2 years 8 months ago
(03-Aug-2023)
11/17 (64.71%)
$29.14 (15.27%)
326
Buy Since 07-Jun-2023
$215
$40.04 (22.89%)
$200
2 years 8 months ago
(03-Aug-2023)
7/10 (70%)
$24.14 (12.65%)
211
Buy Since 08-Feb-2018
$225
$50.04 (28.60%)
$184
2 years 8 months 2 days ago
(01-Aug-2023)
13/14 (92.86%)
$36.39 (19.29%)
480
Which stock is Glen Santangelo is most bullish on?
Which stock is Glen Santangelo is most reserved on?
What Year was the first public recommendation made by Glen Santangelo?
